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Abstract
Introduction For decisions on glioblastoma surgery, the risk of complications and decline in performance is decisive. In 
this study, we determine the rate of complications and performance decline after resections and biopsies in a national quality 
registry, their risk factors and the risk-standardized variation between institutions.
Methods Data from all 3288 adults with first-time glioblastoma surgery at 13 hospitals were obtained from a prospective 
population-based Quality Registry Neuro Surgery in the Netherlands between 2013 and 2017. Patients were stratified by 
biopsies and resections. Complications were categorized as Clavien-Dindo grades II and higher. Performance decline was 
considered a deterioration of more than 10 Karnofsky points at 6 weeks. Risk factors were evaluated in multivariable logistic 
regression analysis. Patient-specific expected and observed complications and performance declines were summarized for 
institutions and analyzed in funnel plots.
Results For 2271 resections, the overall complication rate was 20 % and 16 % declined in performance. For 1017 biopsies, 
the overall complication rate was 11 % and 30 % declined in performance. Patient-related characteristics were significant 
risk factors for complications and performance decline, i.e. higher age, lower baseline Karnofsky, higher ASA classification, 
and the surgical procedure. Hospital characteristics, i.e. case volume, university affiliation and biopsy percentage, were not. 
In three institutes the observed complication rate was significantly less than expected. In one institute significantly more 
performance declines were observed than expected, and in one institute significantly less.
Conclusions Patient characteristics, but not case volume, were risk factors for complications and performance decline after 
glioblastoma surgery. After risk-standardization, hospitals varied in complications and performance declines.
Keywords Glioblastoma · Neurosurgical procedures · Postoperative complications · Karnofsky performance status · 
Quality of health care · Patient outcome assessment
Introduction
For patients with glioblastoma, neurosurgeons aim to maxi-
mize tumor removal, while preserving functional integrity, 
to prolong patient survival with acceptable quality of life [1]. 
Based on various factors, including age, symptoms, general 
condition, comorbidity, tumor location and extent, perceived 
balance between procedural risks and anticipated benefit and 
patient preference, the decision is sometimes made to biopsy 
rather than to resect, and to limit the extent of resection. An 
important argument to make neurosurgical decisions and to 
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counsel patients is the risk of complications and a decline 
in performance.
  Standards are lacking for the indication to biopsy and 
for the extent of tumor removal. Consequently a large range 
of options is available for neurosurgical teams which can 
be considered an opportunity for highly patient-tailored 
decisions, but at the same time could result in consider-
able practice variation and therefore outcome variation. We 
have previously reported on variation in 30-day mortality 
and 2-year survival outcome among institutes from the same 
registry [2].
The literature contains surgical reports with varying 
rates of adverse events after glioblastoma surgery. Instead 
of selectively citing the rate that suits the present decision 
best, it is probably better to use real-world data as source for 
arguments in these neurosurgical decisions, preferably using 
one’s own outcome data. To this end the Dutch Society for 
Neurosurgery has initiated a quality registry, which contains 
outcome data from all patients who had glioblastoma sur-
gery in all institutes.
In this study, we determine the rate and severity of com-
plications and Karnofsky performance decline after resec-
tions and biopsies in a nation-wide quality registry, their 
risk factors and the risk-standardized variation between 
institutions.
Materials and methods
Dutch quality registry neuro surgery
The Dutch Society for Neurosurgery (http://www.nvvn.org) 
established the Quality Registry for Neuro Surgery in 2011 
(http://www.qrns.nl). This registry aims to provide feedback 
to all institutions with neurosurgical units on patient out-
comes and treatment variation for self-assessment and qual-
ity-monitoring. Neurosurgeons, nurse specialists in neuro-
oncology and trained physician assistants prospectively enter 
patient data in the registry. Participation in the registry is 
mandatory for all intitutions providing glioblastoma sur-
gery. Each institution is represented in the collaborative for 
glioblastoma surgery with several meetings per year for the 
methods design and interpretation of results. Outcomes are 
reported to the Dutch Society for Neurosurgery annually.
Patients
  We studied all 3288 patients who had first-time surgery for 
glioblastoma at all 13 hospitals in the Netherlands. Patients 
had their surgery between 1/1/2013, when the complication 
severity was included, and 12/31/2017. We collected data for 
patients 18 years or older at surgery and a histopathological 
diagnosis of glioblastoma according to the WHO 2007 cri-
teria until 2015 and the WHO 2016 criteria thereafter [3].
Data collection
Demographic and clinical information consisted of age at 
diagnosis, gender, Karnofsky performance status before 
surgery, type of surgery (biopsy or resection), and dates of 
treatment, last follow-up and death. A surgical procedure 
was considered a biopsy, when tissue was taken for diagnosis 
only, either by needle biopsy or open biopsy.
Treatment decisions for patients were made in multidisci-
plinary tumor board meetings in all hospitals. Image-guided 
navigation was available in all hospitals, fluorescence-guid-
ance in ten hospitals, intraoperative stimulation mapping in 
nine hospitals, ultrasound in three hospitals, and intraopera-
tive MRI in none of the hospitals.
Because this data was collected for evaluation of quality 
of care in accordance with the Dutch Quality Act for Health-
care (http://wette n.overh eid.nl/BWBR0 00785 0/2015-01-01) 
and the New Healthcare Quality, Complaints and Disputes 
Act (https ://wette n.overh eid.nl/BWBR0 03717 3/2019-05-
01), individual written informed consent was not needed. 
The study was not subject to the Medical Research Involv-
ing Human Subjects Act (WMO, https ://wette n.overh eid.nl/
BWBR0 00940 8/2018-08-01), therefore ethical approval was 
waived, and de-identified data had been collected of patients 
not alive by a trusted third party (http://www.sivz.nl/en).
Outcome measures and risk predictors
The main outcome measures to evaluate variation were spec-
ified in the consensus item set: the risk-standardized compli-
cations and performance alterations at 6 weeks postopera-
tive. The severity of complications was graded by the revised 
Clavien-Dindo classification. This classification ranks com-
plications based on the therapy used to treat the complica-
tion and has been reported to be an objective, simple, reli-
able, and reproducible way of reporting adverse events after 
surgery [4], and consists of five grades, i.e. I: any deviation 
from normal, not requiring treatment, II: requiring medica-
tion, III: requiring an intervention, IV: requiring intensive 
care management, and V: death. This grading was added 
to the registry in 2013. For institutional comparison, we 
analyzed complication severity as complications of grade 
II and higher. Performance alterations were calculated by 
subtracting the baseline Karnofsky performance score prior 
to surgery from the Karnofsky performance score at 6 weeks 
after surgery. For institutional comparison, negative perfor-
mance change of more than ten points was considered a per-
formance decline [5].
To account for risk differences between institutions, we 
explored these patient-related characteristics as predictors 
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for outcomes: age at surgery, gender, American Society of 
Anesthesiologists physical status (ASA) classification, base-
line Karnofsky performance, and year of treatment; and the 
institution-related characteristics: case volume, university 
hospital, and biopsy percentage.
Statistical analysis
For each patient a risk prediction was calculated based on 
the patient characteristics that were identified in multivari-
able logistic regression models. The model with the lowest 
Akaiki’s information criterium was selected as a trade-off 
between goodness of fit and model simplicity. Patient-spe-
cific risk prediction allowed for risk-standardized compari-
son between expected and observed complication grades and 
performance decline for institutes. To compare outcomes 
between institutes, the expected number of events based on 
an institute’s patient population was plotted against the ratio 
of number of observed and expected events in funnel plots. 
Institutes with achievements outside the 95 % confidence 
intervals were considered significantly deviant from the 
expectation. Institutes, providing less than 85 % of outcome 
measures, were considered to contribute insufficient data and 
their results were therefore uninformative.
Results
Of the 3288 patients, 2271 (69 %) had a resection, the oth-
ers a biopsy only. The complication severity was missing 
for 417 (13 %). A baseline or follow-up performance score 
to calculate the performance change was missing for 440 
(13 %). This was mainly due to 3 of 13 institutes, f, h, and i, 
with more than 15 % of outcome measures missing. Patient 
characteristics per institute and institutional characteristics 
are listed in Table 1.
  The observed complication severity and performance 
changes at 6 weeks postoperative are plotted in Fig. 1 for 
resections and in Fig. 2 for biopsies. For resections over all 
institutes, complications of any severity were observed in 
459 (20 %) patients, grade II or higher in 250 (11 %), grade 
III or higher in 105 (5 %) and grade IV or higher in 41 (2 %) 
(Fig. 1a). Complications of grade II or higher for resections 
ranged between 0 % (institute f) and 19 % (institute g). And 
a performance decline was observed in 359 (16 %) resection 
patients, a stable performance in 1427 (63 %), and a perfor-
mance improvement in 217 (10 %) (Fig. 1c). Performance 
decline for resections varied from 0 % (institute f) to 23 % 
(institute c). For biopsies over all institutes, complications of 
any grade were observed in 112 (11 %) patients, grade II or 
higher in 47 (5 %), grade III or higher in 22 (2 %) and grade 
IV or higher in 12 (1 %) (Fig. 2a). Complications of grade II 
or higher for biopsies varied from 0 % (institute d) to 18 % 
(institute b). And a performance decline was observed in 305 
(30 %) biopsy patients, a stable performance in 518 (51 %), 
and a performance improvement in 22 (2 %) (Fig. 2c). Per-
formance decline for biopsies ranged between 2 % (institute 
h) and 58 % (institute l).
To determine the risk factors for complication severity 
and performance decline, we first plotted the patient and the 
institute characteristics to these outcomes (Supplementary 
Fig. 1). Next, the association between characteristics and a 
complication grade II or higher, or a performance decline 
was evaluated in multivariable logistic regression models. A 
higher risk of a complication grade II or higher was associ-
ated with lower baseline Karnofsky (odds ratio, 95 % con-
fidence interval: 0.97, 0.97–0.98), a higher ASA classifica-
tion (ASA-II to ASA-I: 1.6, 1.1–2.2; ASA-III to ASA-I: 1.8, 
1.2–2.8; ASA-IV to ASA-I: 3.0, 1.0-7.9; ASA-V to ASA-I: 
1.2, 0.1–11), and a resection (compared to a biopsy: 2.7, 
1.9–3.8). This model has an AIC of 1774 and the interac-
tion terms were not significantly associated. Year of treat-
ment, patient age and gender were not associated with a 
complication grade II or higher. A higher risk of perfor-
mance decline of more than 10 points was associated with 
a higher age (1.02, 1.01–1.03), higher ASA classification 
(ASA-II to ASA-I: 1.2, 0.97–1.6; ASA-III to ASA-I: 1.6, 
1.1–2.2; ASA-IV to ASA-I: 2.6, 1.0-6.3; ASA-V to ASA-I: 
5.8, 0.93-45) and a biopsy (compared to a resection: 2.3, 
1.9–2.7). This model has an AIC of 2922 and a significant 
interaction term between age and ASA classification. Year of 
treatment and gender were not associated with performance 
decline. Of note, the institution characteristics overall case 
volume, university hospital and biopsy percentage were not 
associated with complication severity nor with performance 
decline (Supplementary Figs. 1 and 2).
  The between-institution variation in complication 
severity and performance decline is displayed as funnel 
plot for all patients in Fig. 3a, b. Ratios higher than 1.0 
indicate more adverse events than expected based on risk 
standardization. In three institutes, a, c, and j, the number 
of observed patients with complications was significantly 
less than expected (Fig. 3a). In institute l significantly more 
performance declines were observed than expected, and in 
b significantly less (Fig. 3b). Other institutions had ratios 
within the control limits, i.e. observed events were according 
to expectations. As the type of intervention was a strong risk 
factor for outcomes, funnel plots were generated separately 
for the subgroup with a resection (Fig. 1b, d) and for the 
subgroup with a biopsy (Fig. 2b, d).
The correlation between Clavien-Dindo classification and 
the change in Karnofsky performance was low (Kendall’s tau 
correlation: − 0.14, Fig. 3c). No complication was observed 
in 198 (55 %) of 359 resection patients with a performance 
decline and in 228 (75 %) of 305 biopsy patients with a per-
formance decline. Conversely, a performance improvement 
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was observed in 109 (45 %) of 250 resection patients with a 
complication grade II or higher and in 7 (13 %) of 47 biopsy 
patients with a complication grade II or higher.
Discussion
The main findings of this study are: (1) any complication is 
observed in 20 % after resection and in 11 % after biopsy; a 
performance decline was observed in 16 % after resection 
and in 30 % after biopsy, (2) risk factors for a complication 
were lower baseline Karnofsky, higher ASA classification, 
and a resection; risk factors for a performance decline were 
higher age, higher ASA classification and a biopsy; institu-
tional case volume, biopsy percentage and university hospi-
tal were not associated with complications nor performance 
decline, (3) patient outcomes among institutes vary more in 
complications than in performance decline.
Variation between institutions in complication outcomes 
and performance changes has not been published for glio-
blastoma surgery. Compared to the extensive literature on 
benefits of glioblastoma surgery, the literature on adverse 
outcome is limited. In these reports, the definitions of surgi-
cal complications, the classifications of patient condition and 
the timing of assessment are far from uniform. Complica-
tions after glioblastoma resection varied between 15 % [6], 
19 % [7], 23 % [8], 24 % [9], and 68 % [10]. Complications 
of biopsies varied between 3 % [11], 6 % [12], 7 % [13], 8 % 
[14], 9 % [15] ,12 % [16], and 13 % [17]. We now demon-
strate the outcome variation in adverse events after glioblas-
toma surgery among teams using identical definitions and 
risk-standardization.
Some reports have used the Karnofsky performance 
score. The median Karnofsky performance before and after 
surgery were reported as similar [18–21]. The performance 
change is more informative for risk assessment in individual 
patients. For instance, a performance decline was observed 
in 5 % [22], 10 % [23], and 39 % [7].
Other measures of adverse outcome of glioblastoma sur-
gery have been documented. Several reports narrow down 
patient condition to neurologic outcome [24–26]. Yet, others 
have used readmission rate as surrogate marker [6]. Even 
more scarce are reports on health-related quality of life after 
surgery [27, 28].
Apart from divergent complication definitions as a source 
of variation in the literature, the timing of assessment also 
varied: 21 days [9], 30 days [8, 23], 6 weeks [7], 3 months 
[26], and 6 months after surgery [24]. Too early assessment 
would inadvertently include transient neurologic dysfunc-
tions and exclude late complications from surgery. Too late 
assessment would include decline from tumor progression or 


















































































































































































































































































































 Journal of Neuro-Oncology
1 3
6 weeks after surgery, typically immediately before the start 
of radiotherapy.
To compare complication outcomes between neuro-
surgical reports, a consensus definition of complications, 
their severity and their timing of assessment is essential. 
Few classifications have been proposed [29–32]. Ambigu-
ity arises in classifying adverse events when judgment of 
deviation from the expected course is required. We have cho-
sen to use the revised Clavien-Dindo classification, because 
it avoids this ambiguity from expectations and allows for 
direct comparison with other surgical procedures. In general 
surgery this has been proven to be an objective, simple, reli-
able, and reproducible way of reporting adverse postopera-
tive events [4, 33]. This classification is based on the type of 
therapy required to treat the complication and was devised to 
eliminate subjective interpretation of serious adverse events, 
because it is based on events that are usually well-docu-
mented and easily verified. To put the observed complica-
tion risk of glioblastoma surgery into perspective, any com-
plication was observed in 10 % after radical prostatectomy 
[34], 29 % after hepatocellular carcinoma resections [35], 
29 % after noncardiac thoracic operations [36], 47 % after 
pancreatic adenocarcinoma resections [37], and 61 % after 
pancreaticoduodenectomies [38].
The Clavien-Dindo classification and the change in Kar-
nofsky performance can both detect adverse surgical events, 
although these measure different aspects of patient outcome 
and their correlation was low. Others have observed more 
performance decline in patients with higher grade compli-
cations in a general neurosurgical population [30, 39]. An 
explanation for the discordance between the two measures 
in our data may be that post-operative neurological deficit 
is not scored in the Clavien-Dindo classification, when it 
does not require additional treatment. Another explanation 
may be that not every performance decline is due to surgical 
complications, but can also be due to early glioblastoma pro-
gression. We have previously identified early progression as 
frequent cause of death within 30 days [2]. Early progression 
may also explain the discordance between 30 % performance 
decline after biopsy and 16 % decline after resection.
Fig. 1  Distributions of a Clavien-Dindo complication severity and c 
Karnofsky performance changes for resection patients per institute, 
sorted by volume of resection cases over 5 years and funnel plots 
for observed and expected b  complication grade II or higher and 
d performance decline. The color codes are provided in the legends. 
Each dot represents an institute indicated by a letter corresponding 
to Table 1. Blue dots indicate institutes with less than 15 % outcome 
measures missing, grey dots institutes with more than 15 % missing. 
The solid funnels are 95 % control limits, the dotted funnels 99 % con-
trol limits
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The implications for clinical practice from this work are 
that the risk factors for complications, i.e. lower baseline 
Karnofsky and higher ASA classification, can be used for 
patient counseling. For example, consider two patients indi-
cated for a resection: a 75-year-old patient with a KPS of 70, 
and an ASA classification of III, and a 25-year-old patient 
Fig. 2  Distributions of a Clavien-Dindo complication severity and 
c Karnofsky performance changes for biopsy patients per institute, 
sorted by volume of biopsy cases over five years and funnel plots 
for observed and expected b complication grade II and higher and 
d performance decline. The color codes are provided in the legends. 
Each dot represents an institute indicated by a letter corresponding 
to Table 1. Blue dots indicate institutes with less than 15 % outcome 
measures missing, grey dots institutes with more than 15 % missing. 
The solid funnels are 95 % control limits, the dotted funnels 99 % con-
trol limits
Fig. 3  Funnel plot for all patients per institute of risk-standardized 
expected number of events and the ratio of observed and expected 
number of events for a a complication grade II and higher, and b for 
a performance decline of more than ten points. Each dot represents 
an institute indicated by a letter corresponding to Table 1. Blue dots 
indicate institutes with less than 15 % outcome measures missing, 
grey dots institutes with more than 15 % missing. The solid funnels 
are 95 % control limits, the dotted funnels 99 % control limits. Corre-
lation between complication grades and performance changes (c)
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with a KPS of 90, and an ASA classification of I. The first 
patient has a risk of 18 % for a relevant complication and 
24 % for performance decline, whereas the second patient 
7 % and 14 %, respectively (see also https ://nvvn-qrns-gbm.
shiny apps.io/patie nt_risk_predi ction /). Ideally, patient coun-
seling should be based on institute-specific data, which is 
now available for these hospitals. Others have identified 
higher age and tumor location as risk factors for complica-
tions [10, 23]. The systematic collection of imaging charac-
teristics has been scheduled for our registry from 2020 to be 
able to evaluate tumor volume and location as determinant 
of patient outcome in future analyses.
  The discussions based on these results in the registry 
collaborative and in the institutions have been constructive 
and should contribute to outcome improvement programs 
for all institutes. Nevertheless this improvement has yet to 
be determined. A recent systematic review on the effective-
ness of quality improvement collaboratives showed a statisti-
cally significant improvement of at least 50 % of the primary 
outcome in 73 % of studies [40]. The elements for success 
from collaboratives have not been identified [41, 42]. The 
aim for our collaborative on glioblastoma surgery is to fur-
ther reduce complications and performance decline, rather 
than facilitate regression to a common mean outcome with 
no outliers. We will expand the registry with more detailed 
neurological outcome and complication diagnosis to be able 
to address potential strategies for improvement.
Strengths of this study include a comprehensive popu-
lation-based nation-wide prospective registry with stand-
ardized definitions of severity and timing of complications 
and performance decline. As limitations, we did not specify 
the neurological outcomes, the complication diagnosis and 
potential causes and we did not measure the health-related 
quality of life. Imaging data including tumor volume and 
location was so far not systematically collected and conse-
quently risk-standardization could be improved. Some treat-
ment-related characteristics that may be of interest as predic-
tors were not systematically collected in the registry, such as 
corticosteroid use, surgical technique and extent of resection. 
Data verification by audits could support the data quality.
Conclusions
Any complication in glioblastoma surgery is observed in 
11 % after biopsy and in 20 % after resection, and a per-
formance decline was observed in 30 % after biopsy and in 
16 % after resection. The risk factors for a complication were 
lower baseline Karnofsky, higher ASA classification, and a 
resection. The risk factors for a performance decline were 
higher age, higher ASA classification and a biopsy. Institu-
tion case volume, academic status and biopsy percentage 
were not associated with complications nor performance 
decline. Complications and performance declines vary 
between hospitals.
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